<DOC>
	<DOCNO>NCT01114555</DOCNO>
	<brief_summary>The purpose study find good safe combination irinotecan , temozolomide bevacizumab patient resistant recurrent neuroblastoma . These drug give separately patient , never give together . Irinotecan temozolomide two drug use together treat neuroblastoma many people . These drug consider chemotherapy . Bevacizumab another drug use treat cancer . It make company call Genentech . Bevacizumab antibody . Antibodies proteins find blood attach bacteria virus . Bevacizumab attach special protein bloodstream . This protein help tumor grow new blood vessel . Blood vessel carry nutrient feed tumor . Bevacizumab think block growth new blood vessel starve tumor . It use treatment many cancer adult . It approve FDA treatment adult colon cancer cancer people neuroblastoma . There small amount information know use drug child . It use irinotecan treat cancer child neuroblastoma .</brief_summary>
	<brief_title>Bevacizumab , Irinotecan Temozolomide Relapsed Refractory Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must diagnosis NB accordance International Criteria , i.e. , either histopathology ( confirm MSKCC Department Pathology ) BM involvement plus elevated urinary catecholamine . Must history tumor progression recurrence failure achieve complete response standard therapy . Patients must evaluable ( microscopic marrow metastasis , MIBG PET scan ) measurable ( CT , MRI ) disease . Patients age eligible . Prior Therapy : At least 2 week elapse since biologic therapy . Three week elapse since last dose chemotherapy . Minimum life expectancy eight week . Signed informed consent indicate awareness investigational nature program . Severe major organ toxicity . Renal , cardiac , hepatic , pulmonary , gastrointestinal neurologic toxicity grade 2 less ( per NCI CTC version 4.0 criterion ) . Specifically , serum creatinine ≤3 x upper limit normal ( ULN ) , serum AST ALT ≤5 x ULN , serum bilirubin ≤ 3 x ULN , LV shorten fraction ≥15 % . Patients myelosuppression exclude ANC ≥ 500/uL . Platelet count &gt; 35,000/ul hemoglobin &gt; 8gm/dl . Patients receive filgrastim , platelet red blood cell transfusion 2 day prior achieve ANC , platelet hemoglobin level . Patients document chronic nonhealing wound , ulcer bone fracture Surgical procedure . Patients undergone major surgery &lt; 28 day prior begin therapy bevacizumab exclude . Patients must least 24 hour surgical procedure placement central catheter . Patients &lt; 7days minor surgery ( e.g . fine needle core biopsy ) and/or unhealed wound procedure exclude . Patients exclude major surgery ( e.g . abdominal thoracic surgery resection tumor ) anticipate course study . Known bleed diathesis coagulopathy ( absence therapeutic anticoagulation ) Thrombosis : patient must deep venous arterial thrombosis ( noncentral venous catheter relate ) within last three month prior study entry . Patients cerebrovascular accident transient ischemic attack within 6 month therapy exclude . Patients history peripheral vascular disease , myocardial infarction unstable angina exclude . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study entry . Known CNS metastasis , except treat brain metastasis . Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement except dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include radiotherapy , chemotherapy immunotherapy Patients CNS metastasis treat neurosurgical resection biopsy perform within 3 month treatment exclude . Proteinuria : Urine protein : creatinine ratio ≥ 1.0 . Uncontrolled ( last &gt; 24 hrs antihypertensive medication ) hypertension define ageappropriate criterion . Hypertension define average systolic blood pressure and/or diastolic blood pressure 95th percentile gender , age , height 3 occasions93 . 95th percentile gender , age height provide Appendix A . For patient ≥18 year age , hypertension define systolic blood pressure &gt; 150mmHg and/or diastolic blood pressure &gt; 100mmHg . Prior history hypertensive crisis hypertensive encephalopathy History hypersensitivity component bevacizumab History hemoptysis ( ≥ 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 . Active serious infection control antibiotic . Pregnant woman exclude fear danger fetus . Therefore negative pregnancy test require woman childbearing age , appropriate contraception use study period . Inability unwillingness comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>10-015</keyword>
</DOC>